Find and Join

• Let’s talk about that Lilly announcement

  There’s been plenty of coverage of Eli Lilly’s announcement this week that it will sell vials of Zepbound directly to consumers at a discount. But the company seems to have left out a few important caveats. read more →

• Our response to the op-ed in The Hill

  The Hill published an editorial by Dr. Kenneth McCall titled “Fake, unsafe weight-loss drugs are a worsening public health dilemma” in which he makes unfounded claims about pharmacy compounding. Here’s the response from our CEO. read more →

• The shortage ends … then what? (Find out at CCH) 

  We’ve added a new session to the Compounders on Capitol Hill lineup. Don’t miss the discussion of what’s on many a compounder’s (and regulators’ … and reporters’...) mind. read more →

• A new bronze corporate patron

  A big welcome to Ro, APC’s newest tier-level corporate patron! read more →

• Education (and CE) from USP

  For the fourth year in a row, USP will be holding a hybrid live/virtual workshop dedicated to improving the quality of compounding. read more →

• Compounding post-Chevron

  At least three issues affecting pharmacy compounding might be affected by the overturning of the decades-old “Chevron doctrine.” read more →

• 503B sourcing: our state-by-state analysis

  Do you work for one of APC’s PFMs? If you’re with a Pharmacy/Facility Member, you’ve got access to a new resource. read more →

• What we’ll be talking about at CCH

  When we get together on Capitol Hill to meet with legislators and their staffs, as much as we’d like to talk about a half-dozen issues (easily!), we’re going to be focusing on the three most important.  read more →

More News

APC this week asked FDA’s Center for Veterinary Medicine to provide additional guidance on compliance with its GFI 256 on animal drug compounding. In a letter to the CVM’s Dr. Bill Flynn, APC raised several issues that have come up in our training sessions for members. 

The letter asks CVM to clarify whether compounded drugs should be allowed when a drug is not available due to supply chain issues or backorders. The FDA had previously said that compounders should contact the agency in case of a drug shortage but that the agency does not provide blanket enforcement discretion for compounding copies of drugs in shortage.

The letter also takes issue with CVM’s assertion that compounders are expected to know what ingredients may be harmful or cause side effects to the species for which the drug is being compounded. 

“Because they are not listed in the approved package insert, it simply is not possible for pharmacists to know the excipients in manufactured animal drug products,” the letter states.